Skip to content

Effects of early used Shenfu injection on hemodynamics in patients with sepsis: a multicenter, randomized, controlled trial

Effects of early used Shenfu injection on hemodynamics in patients with sepsis: a multicenter, randomized, controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006148
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

controlled group:stroke-physiological saline solution
experimental group :Shenfu injection

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria for sepsis (sepsis 3.0) 2.Age: 18-75 years old

Exclusion criteria

Exclusion criteria: 1.Expected ICU stay is less than 24 hours 2.Diagnosed with sepsis for more than 24 hours 3.Diagnosed with obstructive shock 4.Cardiogenic shock caused by acute myocardial infarction, valvular heart disease, dilated cardiomyopathy, restrictive cardiomyopathy, etc 5.History of CPR or advanced malignant tumor 6.Allergy history of Shenfu injection 7.Pregnant or breastfeeding women 8.Severe liver and kidney damage, requiring blood purification during the study 9.Use of immunomodulators or organ transplantation within 6 months 10.Participated in other clinical trials in the past three months 11.Use of other traditional Chinese medicines during the study 12.Other special circumstances are excluded by the clinical staff at the time of registration 13.If a patient misdiagnosed with sepsis is identified, he/she should be removed after enrollment Patients with the following conditions will be withdrawn:(1)leaving the ICU without authorization;(2)incomplete follow-up;(3)poor compliance. Document the reasons for the patient's withdrawal from the study.

Design outcomes

Primary

MeasureTime frame
28-day mortality;

Countries

China

Contacts

Public ContactBo Hu
hobbier1979@163.com18062603223

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026